Linear Clinical Research

Recent papers from Linear Clinical Research

1. Final Analysis of the BRUIN Phase 1/2 Study Assessing the Safety and Efficacy of Pirtobrutinib Monotherapy in Patients With MCLAmerican Journal of Hematology · 2026
2. Neoadjuvant durvalumab and tremelimumab in combination with chemotherapy in newly diagnosed advanced high-grade serous ovarian cancer (iPRIME): a randomized, non-comparative phase 2 trial using chemotherapy response score as the primary endpointCancer Immunology Immunotherapy · 2026
3. Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trialThe Lancet · 2024
4. Phase 1 Trial with Soquelitinib, a Selective ITK Inhibitor for Treatment of Relapsed/Refractory T Cell LymphomasBlood · 2026
5. Elarekibep, an inhaled Anticalin protein, targets IL-4Rα locally: first-in-human randomized phase 1 trials of a novel potential therapeutic class in asthmaRespiratory Research · 2026
6. Tucatinib and trastuzumab in advanced cancers with HER2 mutations or amplifications: a molecular screening and therapeutics (MoST) program substudynpj Precision Oncology · 2026
7. A first-in-class bifunctional antibody targeting CD20 and CD37 remodels the immune microenvironment in relapsed or refractory B-cell malignanciesJournal of Hematology & Oncology · 2026
8. A global phase 1/2a trial of SHR-A1904, a CLDN18.2-targeting ADC, in advanced solid tumors expressing CLDN18.2.Journal of Clinical Oncology · 2026
9. Updated design of INVOKE: A phase 1 study of OKN4395, a first-in-class EP2/EP4/DP1 triple prostanoid receptor antagonist, in patients with advanced solid tumors.Journal of Clinical Oncology · 2026
10. Phase 1/2 study of CLIO-8221, a HER2-targeted, dual-payload exatecan and ATR inhibitor antibody-drug conjugate (ADC) in patients with advanced HER2-expressing solid tumors.Journal of Clinical Oncology · 2026
11. A phase 1 study of BGB-A3055 (anti-CCR8) with or without tislelizumab (anti–PD-1) in patients with solid tumors.Journal of Clinical Oncology · 2026
12. Re-sensitizing PD-1/PD-L1 relapsed/refractory solid tumors: Phase 1a results of IOS-1002, a LILRB1/2 and KIR3DL1 checkpoint inhibitor, in combination with pembrolizumab.Journal of Clinical Oncology · 2026
13. RAISIC-1: A phase 1/2 clinical trial of the GPR65 inhibitor PTT-4256—Preliminary safety, tolerability, pharmacokinetic, and pharmacodynamic results.Journal of Clinical Oncology · 2026
14. B15-09 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBT002, a Novel Bispecific IL-4Rα/IL-5 Antibody: Results From the Single- and Multiple-ascending Dose Healthy Volunteers Portions of a Phase I StudyAmerican Journal of Respiratory and Critical Care Medicine · 2026
15. Clinical Utility of Stillbirth Investigations in Australia: A Cohort StudyAustralian and New Zealand Journal of Obstetrics and Gynaecology · 2026
16. Abstract CT086: A phase 1/2, first-in-human study of an ADC targeting CDH17 (DB-1324) in participants with advanced/metastatic gastrointestinal tumorCancer Research · 2026
17. Abstract CT060: First in human phase 1 study of D3S-002, a purposely designed ERK1/2 inhibitor, in advanced solid tumors with MAPK pathway mutationsCancer Research · 2026
18. Marginal Zone Lymphoma: 2026 Update on Diagnosis and ManagementAmerican Journal of Hematology · 2026
19. Genomic Therapy Matching in Rare and Refractory CancersJAMA Oncology · 2026
20. Ascending dose escalation of belzutifan plus palbociclib for previously treated advanced clear cell renal cell carcinoma (ccRCC): Phase 1/2 LITESPARK-024 study part 1.Journal of Clinical Oncology · 2026